Flashback Foreword: Anti-HER2 Monoclonal Antibody as a Single Agent

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. February 28, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02679 Journal of Clinical Oncology - published online before print March 7, 2023 PMID: 36881997 Flashback Foreword: Anti-HER2 Monoclonal Antibody as a Single Agent Pamela J. Goodwin , MD, MSc1,2xPamela J. GoodwinSearch for articles by this author Show More 1Department of Medicine, Sinai Health System, University of Toronto, Toronto, Ontario, Canada2Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02679 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 1999, Cobleigh et al1 demonstrated important activity of a single-agent recombinant humanized monoclonal antibody (now known as trastuzumab) targeting the human epidermal growth factor receptor (HER2) in women with pretreated metastatic HER2-positive breast cancer. This, along with subsequent studies of trastuzumab and other agents targeting HER2 in the metastatic and (neo)adjuvant settings, has revolutionized the management of HER2-positive breast cancer, leading to dramatic improvements in outcomes in both the early and metastatic settings.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Anti-HER2 Monoclonal Antibody as a Single AgentThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Pamela J. GoodwinResearch Funding: Epic Sciences (Inst)No other potential conflicts of interest were reported. Companion Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease